Resveratrol: Effects on Lipids and Cardiovascular Risk

Current Cardiovascular Risk Reports

Volumn 7, Issue 1, 2013, Pages 9-16

  Cherniack, E Paul ^a,b   Troen, Bruce R ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adipocytes; Cardiovascular disease; Inflammation; Lipids; Oxidative stress; Resveratrol

Indexed keywords

CHOLESTEROL; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; NITROUS OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; RESVERATROL; SUPEROXIDE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENDOTHELIUM CELL; HUMAN; LIPOGENESIS; LIPOLYSIS; NONHUMAN; OBESITY; OXIDATIVE STRESS; REVIEW; VASCULARIZATION;

EID: 84872283843     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-012-0289-2     Document Type: Review

References (99)

1. Vidavalur R, Otani H, Singal PK, Maulik N. Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Exp Clin Cardiol. 2006; 11: 217-25.
2. Hansel B, Kontush A, Bruckert E. Is a cardioprotective action of alcohol a myth? Curr Opin Cardiol. 2012; 27: 550-5.
3. Pai JK, Mukamal KJ, Rimm EB. Long-term alcohol consumption in relation to all-cause and cardiovascular mortality among survivors of myocardial infarction: the Health Professionals follow-up study. Eur Heart J. 2012; 33: 1598-605.
4. Romelsjo A, Allebeck P, Andreasson S, Leifman A. Alcohol, mortality, and cardiovascular events in a 35 year follow-up of a nationwide representative cohort of 50, 000 Swedish conscripts up to age 55. Alcohol Alcohol. 2012; 47: 322-7.
5. Gronbaek M, Deis A, Sorensen TI, Becker U, Schnohr P, Jensen G. Mortality associated with moderate intakes of wine, beer, or spirits. BMJ. 1995; 310: 1165-9.
6. St Leger AS, Cochrane AL, Moore F. Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine. Lancet. 1979; 1: 1017-20.
7. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem. 2005; 280: 17187-95.
8. Fischer-Posovszky P, Kukulus V, Tews D, et al. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr. 2010; 92: 5-15.
9. Beher D, Wu J, Cumine S, et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des. 2009; 74: 619-24.
10. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature. 2006; 14(444): 868-74.
11. Knutson MD, Leeuwenburgh C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr Rev. 2008; 66: 591-6.
12. Baur JA. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev. 2010; 131: 261-9.
13. Yang JY, Della-Fera MA, Rayalam S, et al. Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci. 2008; 82: 1032-9.
14. Ahn J, Lee H, Kim S, Ha T. Resveratrol inhibits TNF-alpha-induced changes of adipokines in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2007; 364: 972-7.
15. Mader I, Wabitsch M, Debatin KM, Fischer-Posovszky P, Fulda S. Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis. FASEB J. 2010; 24: 1997-2009.
16. Szkudelska K, Nogowski L, Szkudelski T. Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J Steroid Biochem Mol Biol. 2009; 113: 17-24.
17. Floyd ZE, Wang ZQ, Kilroy G, Cefalu WT. Modulation of peroxisome proliferator-activated receptor gamma stability and transcriptional activity in adipocytes by resveratrol. Metabolism. 2008; 57(7 Suppl 1): S32-8.
18. Berrougui H, Grenier G, Loued S, Drouin G, Khalil A. A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis. 2009; 207: 420-7.
19. Zou JG, Huang YZ, Chen Q, Wei EH, Hsieh TC, Wu JM. Resveratrol inhibits copper ion-induced and azo compound-initiated oxidative modification of human low density lipoprotein. Biochem Mol Biol Int. 1999; 47: 1089-96.
20. Zou J, Huang Y, Chen Q, Wei E, Cao K, Wu JM. Effects of resveratrol on oxidative modification of human low density lipoprotein. Chin Med J. 2000; 113: 99-102.
21. Belguendouz L, Fremont L, Linard A. Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem Pharmacol. 1997; 53: 1347-55.
22. Zhang X, Xu A, Chung SK, et al. Selective inactivation of c-Jun NH2-terminal kinase in adipose tissue protects against diet-induced obesity and improves insulin sensitivity in both liver and skeletal muscle in mice. Diabetes. 2011; 60: 486-95.
23. Chuang CC, Martinez K, Xie G, et al. Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor- > {alpha}-mediated inflammation and insulin resistance in primary human adipocytes. Am J Clin Nutr. 2010; 92: 1511-21.
24. Gonzales AM, Orlando RA. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr Metab. 2008; 5: 17.
25. Arichi H, Kimura Y, Okuda H, Baba K, Kozawa M, Arichi S. Effects of stilbene components of the roots of Polygonum cuspidatum Sieb. et Zucc. on lipid metabolism. Chem Pharm Bull. 1982; 30: 1766-70.
26. Gomez-Zorita S, Fernandez-Quintela A, Macarulla MT, et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr. 2011; 28: 1-9.
27. Takahashi S, Nakashima Y. Repeated and long-term treatment with physiological concentrations of resveratrol promotes NO production in vascular endothelial cells. Br J Nutr. 2012; 107: 774-80.
28. Elies J, Cuinas A, Garcia-Morales V, Orallo F, Campos-Toimil M. Trans-resveratrol simultaneously increases cytoplasmic Ca(2+) levels and nitric oxide release in human endothelial cells. Mol Nutr Food Res. 2011; 55: 1237-48.
29. Wallerath T, Deckert G, Ternes T, et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation. 2002; 106: 1652-8.
30. Coskun B, Soylemez S, Parlar AI, Tulga Ulus A, Fehmi Katircioglu S, Akar F. Effect of resveratrol on nitrate tolerance in isolated human internal mammary artery. J Cardiovasc Pharmacol. 2006; 47: 437-45.
31. Breen DM, Dolinsky VW, Zhang H, et al. Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism. Atherosclerosis. 2012; 222: 375-81.
32. Padin JF, de Diego AM, Fernandez-Morales JC, et al. Resveratrol augments nitric oxide generation and causes store calcium release in chromaffin cells. Eur J Pharmacol. 2012; 685: 99-107.
33. Park CE, Kim MJ, Lee JH, et al. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med. 2007; 39: 222-9.
34. Skrobuk P, von Kraemer S, Semenova MM, Zitting A, Koistinen HA. Acute exposure to resveratrol inhibits AMPK activity in human skeletal muscle cells. Diabetologia. 2012; 55: 3051-60.
35. Breen DM, Sanli T, Giacca A, Tsiani E. Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem Biophys Res Commun. 2008; 374: 117-22.
36. Chan AY, Dolinsky VW, Soltys CL, et al. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem. 2008; 283: 24194-201.
37. Yang CJ, Lin CY, Hsieh TC, Olson SC, Wu JM. Control of eotaxin-1 expression and release by resveratrol and its metabolites in culture human pulmonary artery endothelial cells. Am J Cardiovasc Discussion. 2011; 1: 16-30.
38. Wang Z, Zou J, Huang Y, Cao K, Xu Y, Wu JM. Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin Med J. 2002; 115: 378-80.
39. Kirk RI, Deitch JA, Wu JM, Lerea KM. Resveratrol decreases early signaling events in washed platelets but has little effect on platelet in whole blood. Blood Cells Mol Dis. 2000; 26: 144-50.
40. Lin KH, Hsiao G, Shih CM, Chou DS, Sheu JR. Mechanisms of resveratrol-induced platelet apoptosis. Cardiovasc Res. 2009; 83: 575-85.
41. Zou J, Huang Y, Chen Q, et al. Suppression of mitogenesis and regulation of cell cycle traverse by resveratrol in cultured smooth muscle cells. Int J Oncol. 1999; 15: 647-51.
42. Ekshyyan VP, Hebert VY, Khandelwal A, Dugas TR. Resveratrol inhibits rat aortic vascular smooth muscle cell proliferation via estrogen receptor dependent nitric oxide production. J Cardiovasc Pharmacol. 2007; 50: 83-93.
43. Catalgol B, Batirel S, Taga Y, Ozer NK. Resveratrol: French paradox revisited. Front Pharmacol. 2012; 3: 141.
44. Movahed A, Yu L, Thandapilly SJ, Louis XL, Netticadan T. Resveratrol protects adult cardiomyocytes against oxidative stress mediated cell injury. Arch Biochem Biophys. 2012; 15(527): 74-80.
45. Ungvari Z, Orosz Z, Rivera A, et al. Resveratrol increases vascular oxidative stress resistance. Am J Physiol Heart Circ Physiol. 2007; 292: H2417-24.
46. Kaga S, Zhan L, Matsumoto M, Maulik N. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1, and vascular endothelial growth factor. J Mol Cell Cardiol. 2005; 39: 813-22.
47. Soares DG, Andreazza AC, Salvador M. Sequestering ability of butylated hydroxytoluene, propyl gallate, resveratrol, and vitamins C and E against ABTS, DPPH, and hydroxyl free radicals in chemical and biological systems. J Agric Food Chem. 2003; 51: 1077-80.
48. Kostyuk VA, Potapovich AI, Suhan TO, de Luca C, Korkina LG. Antioxidant and signal modulation properties of plant polyphenols in controlling vascular inflammation. Eur J Pharmacol. 2011; 658: 248-56.
49. Lv XC, Zhou HY. Resveratrol protects H9c2 embryonic rat heart derived cells from oxidative stress by inducing autophagy: role of p38 mitogen-activated protein kinase. Can J Physiol Pharmacol. 2012; 90: 655-62.
50. Tang Y, Xu J, Qu W, et al. Resveratrol reduces vascular cell senescence through attenuation of oxidative stress by SIRT1/NADPH oxidase-dependent mechanisms. J Nutr Biochem. 2012; 23: 1410-6.
51. Liu Y, Liu G. Isorhapontigenin and resveratrol suppress oxLDL-induced proliferation and activation of ERK1/2 mitogen-activated protein kinases of bovine aortic smooth muscle cells. Biochem Pharmacol. 2004; 67: 777-85.
52. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006; 127: 1109-22.
53. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006; 444: 337-42.
54. Kim S, Jin Y, Choi Y, Park T. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol. 2011; 81: 1343-51.
55. Palsamy P, Sivakumar S, Subramanian S. Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats. Chem Biol Interact. 2010; 186: 200-10.
56. Palsamy P, Subramanian S. Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic beta-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. J Cell Physiol. 2010; 224: 423-32.
57. Palsamy P, Subramanian S. Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Chem Biol Interact. 2009; 179: 356-62.
58. Ramadori G, Gautron L, Fujikawa T, Vianna CR, Elmquist JK, Coppari R. Central administration of resveratrol improves diet-induced diabetes. Endocrinology. 2009; 150: 5326-33.
59. Rimbaud S, Ruiz M, Piquereau J, et al. Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PLoS One. 2011; 6: e26391.
60. Pearson KJ, Baur JA, Lewis KN, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008; 8: 157-68.
61. Rocha KK, Souza GA, Ebaid GX, Seiva FR, Cataneo AC, Novelli EL. Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food Chem Toxicol. 2009; 47: 1362-7.
62. Matos RS, Baroncini LA, Precoma LB, et al. Resveratrol causes antiatherogenic effects in an animal model of atherosclerosis. Arq Bras Cardiol. 2012; 98: 136-42.
63. Rivera L, Moron R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009; 77: 1053-63.
64. Louis XL, Thandapilly SJ, Mohankumar SK, et al. Treatment with low-dose resveratrol reverses cardiac impairment in obese prone but not in obese resistant rats. J Nutr Biochem. 2011; 23: 1163-9.
65. Akar F, Uludag O, Aydin A, et al. High-fructose corn syrup causes vascular dysfunction associated with metabolic disturbance in rats: protective effect of resveratrol. Food Chem Toxicol. 2012; 50: 2135-41.
66. Qin F, Siwik DA, Luptak I, et al. The polyphenols resveratrol and s17834 prevent the structural and functional sequelae of diet-induced metabolic heart disease in mice. Circulation. 2012; 125: 1757-64.
67. Palmieri D, Pane B, Barisione C, et al. Resveratrol counteracts systemic and local inflammation involved in early abdominal aortic aneurysm development. J Surg Res. 2011; 171: e237-46.
68. Lamont KT, Somers S, Lacerda L, Opie LH, Lecour S. Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection. J Pineal Res. 2011; 50: 374-80.
69. Robich MP, Chu LM, Chaudray M, et al. Anti-angiogenic effect of high-dose resveratrol in a swine model of metabolic syndrome. Surgery. 2010; 148: 453-62.
70. Franco JG, Lisboa PC, Lima NS, et al. Resveratrol attenuates oxidative stress and prevents steatosis and hypertension in obese rats programmed by early weaning. J Nutr Biochem. 2012. doi: 10. 1016/j. jnutbio. 2012. 06. 019.
71. Bagul PK, Middela H, Matapally S, et al. Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. Pharmacol Res. 2012; 66: 260-8.
72. Chang CC, Chang CY, Huang JP, Hung LM. Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats. Chin J Physiol. 2012; 55: 192-201.
73. Ghanim H, Sia CL, Korzeniewski K, et al. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab. 2011; 96: 1409-14.
74. Ghanim H, Sia CL, Abuaysheh S, et al. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab. 2010; 95: E1-8.
75. Tome-Carneiro J, Gonzalvez M, Larrosa M, et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol. 2012; 110: 356-63.
76. Crandall JP, Oram V, Trandafirescu G, et al. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci. 2012; 67: 1307-12.
77. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011; 14: 612-22.
78. Zamora-Ros R, Urpi-Sarda M, Lamuela-Raventos RM, et al. High urinary levels of resveratrol metabolites are associated with a reduction in the prevalence of cardiovascular risk factors in high-risk patients. Pharmacol Res. 2012; 65: 615-20.
79. Wong RH, Howe PR, Buckley JD, Coates AM, Kunz I, Berry NM. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis. 2010; 21: 851-6.
80. ClinicalTrials. gov. Effects of resveratrol supplements on vascular health in postmenopausal women. Available at: http://clinicaltrials. gov/ct2/show/NCT01564381?term=resveratrol+cardiovascular& rank=2. Accessed May 16, 2012.
81. ClinicalTrials. gov. Resveratrol and serum Apo A-I. Available at: http://clinicaltrials. gov/ct2/show/NCT01364961?term=resveratrol+cardiovascular& rank=6. Accessed May 16, 2012.
82. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res. 2010; 54: 7-16.
83. Park SJ, Ahmad F, Philp A, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012; 148: 421-33.
84. Tennen RI, Michishita-Kioi E, Chua KF. Finding a target for resveratrol. Cell. 2012; 148: 387-9.
85. Fullerton MD, Steinberg GR. SIRT1 takes a backseat to AMPK in the regulation of insulin sensitivity by resveratrol. Diabetes. 2010; 59: 551-3.
86. Centeno-Baez C, Dallaire P, Marette A. Resveratrol inhibition of inducible nitric oxide synthase in skeletal muscle involves AMPK but not SIRT1. Am J Physiol Endocrinol Metab. 2011; 301: E922-30.
87. Um JH, Park SJ, Kang H, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010; 59: 554-63.
88. Wood JG, Rogina B, Lavu S, et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature. 2004; 430: 686-9.
89. Valenzano DR, Cellerino A. Resveratrol and the pharmacology of aging: a new vertebrate model to validate an old molecule. Cell Cycle. 2006; 5: 1027-32.
90. Kaeberlein M, McDonagh T, Heltweg B, et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem. 2005; 280: 17038-45.
91. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003; 425: 191-6.
92. Miller RA, Harrison DE, Astle CM, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2010; 66: 191-201.
93. Baur JA. Revelations into resveratrol's mechanism. Nat Med. 2012; 18: 500-1.
94. Kelly GS. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2. Altern Med Rev. 2010; 15: 313-28.
95. Arunachalam G, Yao H, Sundar IK, Caito S, Rahman I. SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: Role of resveratrol. Biochem Biophys Res Commun. 2010; 393: 66-72.
96. Sulaiman M, Matta MJ, Sunderesan NR, Gupta MP, Periasamy M, Gupta M. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2010; 298: H833-43.
97. Miyazaki R, Ichiki T, Hashimoto T, et al. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2008; 28: 1263-9.
98. Neves AR, Lucio M, Lima JL, Reis S. Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions. Curr Med Chem. 2012; 19: 1663-81.
99. Minor RK, Baur JA, Gomes AP, et al. SRT1720 improves survival and healthspan of obese mice. Sci Rep. 2011; 1: 70.